Panel Discussion: Transforming Patient Monitoring Through Innovation in Liquid Biopsy Analytes, Detection Sensitivity & Data Interpretation

• What are the most impactful recent innovations in liquid biopsy biomarkers, and how can these be robustly validated and effectively integrated into clinical trial designs?
• How can drug-diagnostic stakeholders build high-value, collaborative frameworks to advance liquid biopsy technologies, particularly in improving detection sensitivity, standardization, and data interpretation?

Speakers:

Carol Peña

Associate VP, Companion Diagnostic Development (Cdx)

Merck

Zheng Feng

Head, Clinical Genomics, Clinical Measurements Sciences

EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany

Jarema Kochan

Senior Director, Clinical Biomarkers, Clinical Development

Eikon Therapeutics

Kris Sachsenmeier

Vice President, Translational Sciences

Compass Therapeutics